#sglt2

Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF #SGLT2 #elililly #boehringer “Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF). The EMPEROR-Preserved trial has shown Jardiance (empagliflozin) can significantly reduce the risk of cardiovascular death or hospitalisation in adults living with HFpEF, with or without diabetes. In a statement, the two pharma companies said the results establish Jardiance as the first SGLT2 inhibitor treatment to show benefit for HFpEF patients. “The EMPEROR-Preserved topline results represent a significant breakthrough in cardiovascular medicine and for people with heart failure, which is an increasingly prevalent public health issue affecting millions of people worldwide,” said Iain Squire, lead investigator for EMPEROR-Preserved in the UK.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD https://lnkd.in/eXt3V8F https://www.instagram.com/p/CRNR8x3jU5s/?utm_medium=tumblr

MSL DAILY PHARMA NEWS - Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial #SGLT2 #PFIZER #STEGLATRO “Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries. Overall, the primary MACE outcome was reported in 11.9% (n=653) of patients treated with STEGLATRO (5 mg and 15 mg doses), compared with 11.9% (n=327) of patients treated with placebo (HR=0.97; 95.6% CI [0.85-1.11]; p<0.001 for non-inferiority). The key secondary endpoints of superiority for ertugliflozin versus placebo were not met. “ Free webinar on “how to become an MSL” https://lnkd.in/gFYBJ2G Or click on our profile. Click below to read further, like and share it and follow us to learn more. Our MSL testimonials: Http://https://lnkd.in/eEfHu4c #MSL #FSTP #MSLcert #medicalscienceliaison https://www.instagram.com/p/CBkbzZjDFjX/?igshid=rn4rlatmac86

Изучение молекул SGLT2 также помогло ученым узнать, что их повышение скорее всего сигнализирует о раке простаты или поджелудочной железы.

Изучение молекул SGLT2 также помогло ученым узнать, что их повышение скорее всего сигнализирует о раке простаты или поджелудочной железы.

Изучение молекул SGLT2 также помогло ученым узнать, что их повышение скорее всего сигнализирует о раке простаты или поджелудочной железы.